Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Change in Account Payables: 2017-2025

Historic Change in Account Payables for Pediatrix Medical (MD) over the last 9 years, with Q3 2025 value amounting to $760000.0.

  • Pediatrix Medical's Change in Account Payables fell 8538.46% to $760000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.0 million, marking a year-over-year decrease of 18657.7%. This contributed to the annual value of $17.3 million for FY2024, which is 196726.4% up from last year.
  • As of Q3 2025, Pediatrix Medical's Change in Account Payables stood at $760000.0, which was down 8538.46% from -$576000.0 recorded in Q2 2025.
  • In the past 5 years, Pediatrix Medical's Change in Account Payables ranged from a high of $10.1 million in Q3 2022 and a low of -$7.6 million during Q1 2025
  • Moreover, its 5-year median value for Change in Account Payables was $863000.0 (2021), whereas its average is $992055.6.
  • Its Change in Account Payables has fluctuated over the past 5 years, first plummeted by 281243.78% in 2022, then skyrocketed by 40650000.0% in 2024.
  • Pediatrix Medical's Change in Account Payables (Quarter) stood at $966000.0 in 2021, then crashed by 282.19% to -$1.8 million in 2022, then surged by 99.94% to -$1000.0 in 2023, then surged by 406500.0% to $4.1 million in 2024, then tumbled by 81.3% to $760000.0 in 2025.
  • Its last three reported values are $760000.0 in Q3 2025, -$576000.0 for Q2 2025, and -$7.6 million during Q1 2025.